BTI BiOasis Technologies Inc

biOasis Technologies Inc. (TSX VENTURE:BTI) announces it has been named one of
the 2013 TSX Venture 50(R) companies. The 2013 TSX Venture 50(R) includes the
top 10 companies in 5 major industry sectors that have been identified as
leaders in providing shareholder value on Canada's junior stock exchange. 


"We are very proud to be recognized for a second year running as one of the top
performing companies in providing shareholder value and being named to the 2013
TSX Venture 50(R)," says Rob Hutchison, CEO of biOasis. "We believe this is a
strong testament to our technology and corporate achievements and to our biOasis
personnel team. We would also thank our loyal shareholder's for their support as
we look forward to another exciting year ahead." 


About the TSX Venture 50(R) 

The TSX Venture 50(R) are the top 10 companies listed on the TSX Venture
Exchange, in each of five major industry sectors - mining, oil & gas, technology
& life sciences, diversified industries and clean technology - based on a
ranking formula with equal weighting given to return on investment, market cap
growth, trading volume and analyst coverage. All data was as of December 31,
2012.


TSX Venture 50(R) is a trade-mark of TSX Inc.

ABOUT BIOASIS

biOasis Technologies Inc. is a biopharmaceutical company headquartered in
Vancouver, Canada. Based on Transcend, biOasis proprietary brain delivery
platform, the Company is focused on creating new drugs that can cross the
blood-brain barrier to address unmet medical needs in the treatment of brain
diseases such as neurodegeneration, metastatic cancer and metabolic diseases.
biOasis trades on the TSX Venture Exchange under the symbol "BTI". For more
information about the Company please visit www.bioasis.ca.


Forward Looking Statements

Certain statements in this press release contain forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995 or
forward-looking information under applicable Canadian securities legislation
that may not be based on historical fact, including without limitation
statements containing the words "believe", "may", "plan", "will", "estimate",
"continue", "anticipate", "intend", "expect" and similar expressions. Such
forward-looking statements or information involve known and unknown risks,
uncertainties and other factors that may cause our actual results, events or
developments, or industry results, to be materially different from any future
results, events or developments express or implied by such forward-looking
statements or information. Such factors include, among others, our stage of
development, lack of any product revenues, additional capital requirements, risk
associated with the completion of clinical trials and obtaining regulatory
approval to market our products, the ability to protect our intellectual
property, dependence on collaborative partners and the prospects for negotiating
additional corporate collaborations or licensing arrangements and their timing.
Specifically, certain risks and uncertainties that could cause such actual
events or results expressed or implied by such forward-looking statements and
information to differ materially from any future events or results expressed or
implied by such statements and information include, but are not limited to, the
risks and uncertainties that: we may not be able to successfully develop and
obtain regulatory approval for p97 as a Physician's Aid to Diagnose Alzheimer's,
or future products in our targeted corporate objectives; our future operating
results are uncertain and likely to fluctuate; we may not be able to raise
additional capital; we may not be successful in establishing additional
corporate collaborations or licensing arrangements; we may not be able to
establish marketing and the costs of launching our products may be greater than
anticipated; we have no experience in commercial manufacturing; we may face
unknown risks related to intellectual property matters; we face increased
competition from pharmaceutical and biotechnology companies; and other factors
as described in detail in our filings with the Canadian securities regulatory
authorities at www.sedar.com. Given these risks and uncertainties, you are
cautioned not to place undue reliance on such forward-looking statements and
information, which are qualified in their entirety by this cautionary statement.
All forward-looking statements and information made herein are based on our
current expectations and we undertake no obligation to revise or update such
forward- looking statements and information to reflect subsequent events or
circumstances, except as required by law.


On Behalf of the Board of Directors

Rob Hutchison, Chairman & CEO 

FOR FURTHER INFORMATION PLEASE CONTACT: 
biOasis Technologies Inc.
Rob Hutchison
Chairman & CEO
(778) 383-3280
rob@bioasis.ca
www.bioasis.ca

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni BiOasis Technologies (TSXV:BTI)
Storico
Da Giu 2023 a Giu 2024